Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Frey A, Marr A, Roux S, Kassell NF.

Neurocrit Care. 2010 Dec;13(3):416-24. doi: 10.1007/s12028-010-9433-3.

PMID:
20838933
2.

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.

Lancet Neurol. 2011 Jul;10(7):618-25. doi: 10.1016/S1474-4422(11)70108-9. Epub 2011 Jun 2.

PMID:
21640651
3.

Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Nowbakht P, Roux S, Kassell N.

Stroke. 2012 Jun;43(6):1463-9. doi: 10.1161/STROKEAHA.111.648980. Epub 2012 Mar 8. Erratum in: Stroke. 2012 Jul;43(7):e68.

4.

Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.

Beck J, Raabe A.

Acta Neurochir Suppl. 2011;110(Pt 2):147-50. doi: 10.1007/978-3-7091-0356-2_26.

PMID:
21125461
5.

Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A; CONSCIOUS-1 Investigators..

Stroke. 2008 Nov;39(11):3015-21. doi: 10.1161/STROKEAHA.108.519942. Epub 2008 Aug 7.

6.

Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.

Acta Neurochir Suppl. 2013;115:27-31. doi: 10.1007/978-3-7091-1192-5_7.

PMID:
22890639
7.

Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.

Wang X, Li YM, Li WQ, Huang CG, Lu YC, Hou LJ.

PLoS One. 2012;7(10):e47778. doi: 10.1371/journal.pone.0047778. Epub 2012 Oct 17.

8.

Method of aneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage.

Ibrahim GM, Vachhrajani S, Ilodigwe D, Kassell NF, Mayer SA, Ruefenacht D, Schmiedek P, Weidauer S, Pasqualin A, Macdonald RL.

Neurosurgery. 2012 Jan;70(1):102-9; discussion 109. doi: 10.1227/NEU.0b013e31822e5a8e.

PMID:
21788917
9.

Vasospasm after aneurysmal subarachnoid hemorrhage: need for further study.

Pearl JD, Macdonald RL.

Acta Neurochir Suppl. 2008;105:207-10. Review.

PMID:
19066110
10.

Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.

Barth M, Capelle HH, Münch E, Thomé C, Fiedler F, Schmiedek P, Vajkoczy P.

Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. Epub 2007 Aug 13.

PMID:
17700991
11.
13.

Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage.

Macdonald RL.

Expert Opin Investig Drugs. 2008 Nov;17(11):1761-7. doi: 10.1517/13543784.17.11.1761 .

PMID:
18922111
14.

Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.

Shen J, Pan JW, Fan ZX, Xiong XX, Zhan RY.

J Neurosurg. 2013 Jul;119(1):180-9. doi: 10.3171/2013.3.JNS121436. Epub 2013 May 3. Review.

PMID:
23641823
15.

Impact of systemic inflammatory response syndrome on vasospasm, cerebral infarction, and outcome after subarachnoid hemorrhage: exploratory analysis of CONSCIOUS-1 database.

Tam AK, Ilodigwe D, Mocco J, Mayer S, Kassell N, Ruefenacht D, Schmiedek P, Weidauer S, Pasqualin A, Macdonald RL.

Neurocrit Care. 2010 Oct;13(2):182-9. doi: 10.1007/s12028-010-9402-x.

PMID:
20593247
16.

Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study.

Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, Kunze E, Matthies C, Ernestus RI, Solymosi L, Roosen K.

Crit Care Med. 2010 May;38(5):1284-90. doi: 10.1097/CCM.0b013e3181d9da1e.

PMID:
20228677
17.

Influence of severe renal impairment on the pharmacokinetics of clazosentan.

Bruderer S, Sasu B, Tsvitbaum N, Dingemanse J.

J Clin Pharmacol. 2011 Mar;51(3):413-21. doi: 10.1177/0091270010368975. Epub 2010 Oct 6.

PMID:
20926750
18.

Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.

Chen G, Tariq A, Ai J, Sabri M, Jeon HJ, Tang EJ, Lakovic K, Wan H, Macdonald RL.

Brain Res. 2011 May 25;1392:132-9. doi: 10.1016/j.brainres.2011.03.068. Epub 2011 Apr 3.

PMID:
21466789
19.

Operative complications and differences in outcome after clipping and coiling of ruptured intracranial aneurysms.

Ayling OG, Ibrahim GM, Drake B, Torner JC, Macdonald RL.

J Neurosurg. 2015 Sep;123(3):621-8. doi: 10.3171/2014.11.JNS141607. Epub 2015 Jun 5.

PMID:
26047409
20.

Patient age and vasospasm after subarachnoid hemorrhage.

Ryttlefors M, Enblad P, Ronne-Engström E, Persson L, Ilodigwe D, Macdonald RL.

Neurosurgery. 2010 Oct;67(4):911-7. doi: 10.1227/NEU.0b013e3181ed11ab.

PMID:
20881555

Supplemental Content

Support Center